BIOREGENX, INC. (FDIT)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2025-Dec-312025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-31
Fiscal PeriodQ4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023
Operating Cash Flow69,636$(71,564$)3,205$37,695$(11,361$)(31,196$)(177,341$)(104,250$)(245,626$)(283,464$)(649,161$)(336,792$)
Investing Cash Flow(3,057$)(6,000$)2,652$0$0$(190,597$)
Purchases of Property and Equipment3,057$0$0$0$189,390$
Financing Cash Flow(44,143$)70,833$16,823$(10,415$)(6,944$)46,442$120,059$282,562$513,370$116,108$410,105$164,739$
End Cash Position69,383$46,947$46,456$83,625$58,404$70,081$57,395$114,158$125,402$57,963$225,319$449,437$616,696$
Exchange Rate Effect0$7,222$(7,197$)(2,059$)3,976$(2,560$)519$1,041$(942$)0$14,938$4,794$
Dividends Paid
Unlevered Free Cash Flow66,579$(71,564$)3,205$37,695$(11,361$)(31,196$)(177,341$)(293,640$)(245,626$)(283,464$)(649,161$)(336,792$)